Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis Tobalina

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Nature Communications|September 8, 2017
An in-silico approach to predict and exploit synthetic lethality in cancer metabolismIñigo Apaolaza, Edurne San José-Eneriz, Luis Tobalina, et al.
Elife|February 15, 2022
Patient-specific Boolean models of signalling networks guide personalised treatmentsArnau Montagud, Jonas Béal, Luis Tobalina, et al.
Bioinformatics (Oxford, England)|January 26, 2015
Context-specific metabolic network reconstruction of a naphthalene-degrading bacterial community guided by metaproteomic dataLuis Tobalina, Rafael Bargiela, Jon Pey, et al.
Cancers|August 26, 2023
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft ModelsAnkur Karmokar, Rebecca Sargeant, Adina M Hughes, et al.
British Journal of Cancer|December 19, 2020
SLFN11 informs on standard of care and novel treatments in a wide range of cancer modelsClaudia Winkler, Joshua Armenia, Gemma N Jones, et al.
Molecular & Cellular Proteomics : MCP|June 21, 2023
Proteomic Dynamics of Breast Cancer Cell Lines Identifies Potential Therapeutic Protein TargetsRui Sun, Weigang Ge, Yi Zhu, et al.
British Journal of Cancer|April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancerMelissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Genome Medicine|August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer modelsAndrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Nature Communications|September 8, 2017
An in-silico approach to predict and exploit synthetic lethality in cancer metabolismIñigo Apaolaza, Edurne San José-Eneriz, Luis Tobalina, et al.
Elife|February 15, 2022
Patient-specific Boolean models of signalling networks guide personalised treatmentsArnau Montagud, Jonas Béal, Luis Tobalina, et al.
Bioinformatics (Oxford, England)|January 26, 2015
Context-specific metabolic network reconstruction of a naphthalene-degrading bacterial community guided by metaproteomic dataLuis Tobalina, Rafael Bargiela, Jon Pey, et al.
Cancers|August 26, 2023
Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft ModelsAnkur Karmokar, Rebecca Sargeant, Adina M Hughes, et al.
British Journal of Cancer|December 19, 2020
SLFN11 informs on standard of care and novel treatments in a wide range of cancer modelsClaudia Winkler, Joshua Armenia, Gemma N Jones, et al.
Molecular & Cellular Proteomics : MCP|June 21, 2023
Proteomic Dynamics of Breast Cancer Cell Lines Identifies Potential Therapeutic Protein TargetsRui Sun, Weigang Ge, Yi Zhu, et al.
British Journal of Cancer|April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancerMelissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Genome Medicine|August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer modelsAndrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.
Pageof 2